Kamada Cash Flow Conversion Efficiency

Latest as of September 2025: 0.039x

Kamada cash flow conversion efficiency. Based on the latest financial reports, Kamada (KMDA) has a cash flow conversion efficiency ratio of 0.039x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA10.42 Million ≈ $27.92K USD) by net assets (ILA265.23 Million ≈ $711.08K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Kamada (2007–2024)

Cash flow conversion efficiency of Kamada from 2007 to 2024. This chart illustrates how Kamada's cash flow conversion efficiency has evolved over time, based on yearly financial data. View today's stock price for Kamada for real-time trading data and today's change.

Kamada Cash Flow Conversion Ratio Explained

Kamada cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Kamada Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Kamada ranked by their cash flow conversion efficiency. Also see Kamada (KMDA) market capitalisation for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Source Capital Closed Fund
NYSE:SOR
-0.093x
Pareto Bank ASA
OL:PARB
-0.015x
Hamborner REIT AG
XETRA:HABA
0.031x
Shaanxi Jinye Science Technology and Education Group Co Ltd
SHE:000812
0.148x
Sino-Argi Leading Biosciences
SHG:603970
-0.219x
Polyplex (Thailand) Public Company Limited
BK:PTL
0.003x
Trilogy Metals Inc
TO:TMQ
-0.009x
ElringKlinger AG
F:ZIL2
0.233x

Annual Cash Flow Conversion Efficiency for Kamada (2007–2024)

The table below shows the annual cash flow conversion efficiency of Kamada from 2007 to 2024. Review Kamada free cash flow efficiency to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 ILA259.46 Million
≈ $695.61K
ILA47.59 Million
≈ $127.60K
0.183x +937.34%
2023-12-31 ILA244.02 Million
≈ $654.21K
ILA4.32 Million
≈ $11.57K
0.018x -89.11%
2022-12-31 ILA176.02 Million
≈ $471.90K
ILA28.59 Million
≈ $76.64K
0.162x +425.62%
2021-12-31 ILA176.82 Million
≈ $474.06K
ILA-8.82 Million
≈ $-23.64K
-0.050x -146.63%
2020-12-31 ILA178.64 Million
≈ $478.92K
ILA19.11 Million
≈ $51.22K
0.107x -47.51%
2019-12-31 ILA135.32 Million
≈ $362.79K
ILA27.57 Million
≈ $73.92K
0.204x +117.11%
2018-12-31 ILA112.38 Million
≈ $301.28K
ILA10.55 Million
≈ $28.27K
0.094x +115.90%
2017-12-31 ILA89.49 Million
≈ $239.92K
ILA3.89 Million
≈ $10.43K
0.043x +52.93%
2016-12-31 ILA66.74 Million
≈ $178.94K
ILA1.90 Million
≈ $5.09K
0.028x +114.74%
2015-12-31 ILA72.51 Million
≈ $194.39K
ILA-13.98 Million
≈ $-37.48K
-0.193x -57.44%
2014-12-31 ILA80.99 Million
≈ $217.14K
ILA-9.92 Million
≈ $-26.59K
-0.122x -185.86%
2013-12-31 ILA89.97 Million
≈ $241.21K
ILA-3.85 Million
≈ $-10.33K
-0.043x +85.28%
2012-12-31 ILA28.39 Million
≈ $76.12K
ILA-8.26 Million
≈ $-22.15K
-0.291x -801.65%
2011-12-31 ILA22.67 Million
≈ $60.79K
ILA940.36K
≈ $2.52K
0.041x -89.67%
2010-12-31 ILA26.49 Million
≈ $71.01K
ILA10.63 Million
≈ $28.50K
0.401x +192.43%
2009-12-31 ILA30.15 Million
≈ $80.83K
ILA-13.09 Million
≈ $-35.10K
-0.434x +56.84%
2008-12-31 ILA12.64 Million
≈ $33.89K
ILA-12.72 Million
≈ $-34.11K
-1.006x -456.76%
2007-12-31 ILA69.57 Million
≈ $186.51K
ILA-12.57 Million
≈ $-33.71K
-0.181x --

About Kamada

TA:KMDA Israel Drug Manufacturers - Specialty & Generic
Market Cap
$378.87 Million
ILA141.32 Billion ILA
Market Cap Rank
#13358 Global
#143 in Israel
Share Price
ILA2450.00
Change (1 day)
+0.04%
52-Week Range
ILA2063.00 - ILA2870.00
All Time High
ILA3940.00
About

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmuniza… Read more